WithdrawnPhase 2NCT00570999
Palifermin After Haploidentical PBSCT
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Society for Blood and Marrow Transplantation
- Principal Investigator
- Ruth Seggewiss, MD, MDUniversity Hospital of Würzburg
- Intervention
- Palifermin(drug)
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2008 – 2013
Study locations (1)
- Dr Ruth Seggewiss, Würzburg, Germany
Collaborators
Amgen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00570999 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07590986Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative NeoplasmUniversité Catholique de Louvain
- RECRUITINGPHASE1NCT07480824To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT07394153Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaGrupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine